The mean positive rate of CD163, which has been reported to be a relatively specific marker of M2 macrophages [32], [33], was 21% (ranging from 1% to 93%) and 35% (ranging from 2% to almost 92%) among breast cancer cells in ER+++ and ER- cases, respectively (p<0.05). Here, CD163 is linked to breast carcinoma.